GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » Beneish M-Score

F-star Therapeutics (F-star Therapeutics) Beneish M-Score : 1.38 (As of May. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is F-star Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 1.38 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for F-star Therapeutics's Beneish M-Score or its related term are showing as below:

FSTX' s Beneish M-Score Range Over the Past 10 Years
Min: -2.82   Med: -0.5   Max: 13.71
Current: 1.38

During the past 3 years, the highest Beneish M-Score of F-star Therapeutics was 13.71. The lowest was -2.82. And the median was -0.50.


F-star Therapeutics Beneish M-Score Historical Data

The historical data trend for F-star Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

F-star Therapeutics Beneish M-Score Chart

F-star Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
Beneish M-Score
- - -2.37

F-star Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.37 -2.82 13.71 1.38

Competitive Comparison of F-star Therapeutics's Beneish M-Score

For the Biotechnology subindustry, F-star Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


F-star Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, F-star Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where F-star Therapeutics's Beneish M-Score falls into.



F-star Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of F-star Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7604+0.528 * 1+0.404 * 1.2348+0.892 * 5.5273+0.115 * 0.8663
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1764+4.679 * 0.004563-0.327 * 1.6273
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Total Receivables was $8.15 Mil.
Revenue was 1.125 + 0 + 2.551 + 17.499 = $21.18 Mil.
Gross Profit was 1.125 + 0 + 2.551 + 17.499 = $21.18 Mil.
Total Current Assets was $49.61 Mil.
Total Assets was $83.72 Mil.
Property, Plant and Equipment(Net PPE) was $3.38 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.67 Mil.
Selling, General, & Admin. Expense(SGA) was $23.28 Mil.
Total Current Liabilities was $14.68 Mil.
Long-Term Debt & Capital Lease Obligation was $10.54 Mil.
Net Income was -18.407 + -18.994 + -12.087 + 4.741 = $-44.75 Mil.
Non Operating Income was -4.323 + -2.479 + -0.591 + 0.178 = $-7.22 Mil.
Cash Flow from Operations was -16.548 + -16.532 + -11.615 + 6.781 = $-37.91 Mil.
Total Receivables was $1.94 Mil.
Revenue was 0.751 + 0 + 2.917 + 0.163 = $3.83 Mil.
Gross Profit was 0.751 + 0 + 2.917 + 0.163 = $3.83 Mil.
Total Current Assets was $76.16 Mil.
Total Assets was $114.80 Mil.
Property, Plant and Equipment(Net PPE) was $4.51 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.76 Mil.
Selling, General, & Admin. Expense(SGA) was $23.88 Mil.
Total Current Liabilities was $8.84 Mil.
Long-Term Debt & Capital Lease Obligation was $12.41 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(8.145 / 21.175) / (1.938 / 3.831)
=0.384652 / 0.505873
=0.7604

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.831 / 3.831) / (21.175 / 21.175)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (49.609 + 3.38) / 83.717) / (1 - (76.161 + 4.512) / 114.798)
=0.367046 / 0.297261
=1.2348

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=21.175 / 3.831
=5.5273

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.757 / (0.757 + 4.512)) / (0.672 / (0.672 + 3.38))
=0.143671 / 0.165844
=0.8663

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(23.282 / 21.175) / (23.877 / 3.831)
=1.099504 / 6.232576
=0.1764

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((10.537 + 14.675) / 83.717) / ((12.41 + 8.835) / 114.798)
=0.301157 / 0.185064
=1.6273

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-44.747 - -7.215 - -37.914) / 83.717
=0.004563

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

F-star Therapeutics has a M-score of 1.38 signals that the company is likely to be a manipulator.


F-star Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of F-star Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


F-star Therapeutics (F-star Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
Executives
Geoffrey Race director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Edward Jr Benz director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Darlene M Deptula-hicks officer: See Remarks C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Eliot Forster director, officer: PRESIDENT AND CEO C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Nessan Bermingham director 890 WINTER STREET, WALTHAM MA 02451
Louis Kayitalire officer: CHIEF MEDICAL OFFICER C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Neil Brewis officer: CHIEF SCIENTIFIC OFFICER C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pamela M. Klein director 35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748
Krol Patrick Johan Hendrik director GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Garrett Winslow officer: General Counsel and Secretary 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Lori Firmani officer: VP of Finance and Treasurer 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748
Scott Andrew Smith director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Timothy P Clackson director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christiana Bardon director, 10 percent owner 86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Mpm Oncology Impact Management Lp 10 percent owner 399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116

F-star Therapeutics (F-star Therapeutics) Headlines

From GuruFocus